Scholarlink

Purpose <p>Ketamine use is a potentially modifiable risk factor for hallucinations. We aimed to use target trial emulation to investigate the association between low-dose ketamine and development of hallucinations in critically ill patients in the intensive care unit (ICU).</p> Methods <p>Retrospective study using data from a university affiliated ICU in Melbourne, Australia. Application of marginal structural models and parametric g-formulas to assess the impact of low-dose ketamine on the development of hallucinations.</p> Results <p>We studied 7514 patients from June 2016 to April 2021. Of these, 625 patients (8%) received low-dose ketamine, beginning at a median of 0 (0–1) days from ICU admission and at a mean daily dose of 0.11 (0.08–0.15) mg/kg/h. Low-dose ketamine treated patients had a higher rate of hallucinations within 30&#xa0;days of ICU admission (26% vs. 7%; <i>p</i> &lt; 0.001) and the first episode of hallucination occurred earlier than in unexposed patient (2 [1–3] vs. 3 [1–7] days from ICU admission; <i>p</i> &lt; 0.001). After adjustment for baseline and time-dependent confounders, low-dose ketamine was associated with a higher risk of hallucinations within 30&#xa0;days (OR, 6.46 [95% CI 5.17–8.07]; <i>p</i> &lt; 0.001). These findings were confirmed with parametric g-formulas.</p> Conclusions <p>In ICU patients, low-dose ketamine was strongly associated with an increased risk of hallucinations. However, these findings should be interpreted with caution due to the observational nature of the study and the risk of residual confounding.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of low-dose ketamine with hallucinations in critically ill patients: a target trial emulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月5日

查看全文
  • Ary Serpa Neto,
  • Marcus Young,
  • Jian Wen Chan,
  • Natasha E. Holmes,
  • Kartik Kishore,
  • Dinesh Pandey,
  • Hossein Jahanabadi,
  • Andrew Casamento,
  • Rinaldo Bellomo

摘要

Purpose

Ketamine use is a potentially modifiable risk factor for hallucinations. We aimed to use target trial emulation to investigate the association between low-dose ketamine and development of hallucinations in critically ill patients in the intensive care unit (ICU).

Methods

Retrospective study using data from a university affiliated ICU in Melbourne, Australia. Application of marginal structural models and parametric g-formulas to assess the impact of low-dose ketamine on the development of hallucinations.

Results

We studied 7514 patients from June 2016 to April 2021. Of these, 625 patients (8%) received low-dose ketamine, beginning at a median of 0 (0–1) days from ICU admission and at a mean daily dose of 0.11 (0.08–0.15) mg/kg/h. Low-dose ketamine treated patients had a higher rate of hallucinations within 30 days of ICU admission (26% vs. 7%; p < 0.001) and the first episode of hallucination occurred earlier than in unexposed patient (2 [1–3] vs. 3 [1–7] days from ICU admission; p < 0.001). After adjustment for baseline and time-dependent confounders, low-dose ketamine was associated with a higher risk of hallucinations within 30 days (OR, 6.46 [95% CI 5.17–8.07]; p < 0.001). These findings were confirmed with parametric g-formulas.

Conclusions

In ICU patients, low-dose ketamine was strongly associated with an increased risk of hallucinations. However, these findings should be interpreted with caution due to the observational nature of the study and the risk of residual confounding.